Methods for treating autoimmune disorders, and reagents related thereto
AssigneesTrustees of Tufts College, The Brigham and Women's Hospital, Inc.
InventorsWilliam W. Bachovchin, Vijay K. Kuchroo
Life of this patent
Estimating the term…
Abstract
The invention generally relates to improved methods for treatment or prophylaxis in animal subjects (including humans) of autoimmune disorders including Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease.
Claims11
A method for treating an autoimmune disease in an animal, comprising administering to said animal a composition comprising one or more inhibitors of DPIV in an amount sufficient to suppress the immune system to treat said autoimmune disease, wherein said autoimmune disease is selected from the group consisting of multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis, Grave's disease, and type II collagen-induced arthritis;
- and said inhibitor of DPIV is represented by the formula:
- wherein
- R1 represents hydrogen, lower alkyl;
- R2 represents a branched lower alkyl, cycloalkyl, or cycloalkylalkyl;
- R3 represents hydrogen;
- R4 represents hydrogen, or a C-terminally linked naturally-occurring α-amino acid residue selected from the group consisting of glycine, alanine, valine, cysteine, leucine, isoleucine, serine, threonine, methionine, glutamic acid, aspartic acid, glutamine, asparagine, lysine, arginine, proline, histidine, phenylalanine, tyrosine, and tryptophan;
- W represents
- and
- Y1 and Y2 are, independently, OH, or connected via a ring having from 5 to 8 atoms in a ring structure.
A method for treating an autoimmune disease in an animal, comprising administering to said animal a composition comprising one or more inhibitors of DPIV in an amount sufficient to suppress the immune system to treat said autoimmune disease, wherein said autoimmune disease is selected from the group consisting of multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis, Grave's disease, and type II collagen-induced arthritis;
- and said inhibitor of DPIV is represented by the formula:
- wherein:
- R1 represents hydrogen, lower alkyl;
- R2 represents a branched lower alkyl, cycloalkyl, or cycloalkylalkyl;
- R3 represents hydrogen;
- W represents
- and
- Y1 and Y2 are, independently, OH, or connected via a ring having from 5 to 8 atoms in a ring structure;
- Y1 and Y2 represent independently hydroxyl;
- R2 represents cyclohexyl;
- and
- R3 and R4, represent, independently and for each occurrence, hydrogen.
Dependencies are inferred from the claim text.